Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amosartan Q
- Development stage
- Phase 1
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Amosartan Q is a fixed-dose combination pharmaceutical tablet developed for the integrated treatment of hypertension and hyperlipidemia. It combines three active ingredients—amlodipine (a calcium channel blocker), losartan (an angiotensin II receptor blocker), and rosuvastatin (a statin)—to provide simultaneous blood pressure reduction and cholesterol lowering in a single pill. This combination aims to improve medication compliance in patients who require both antihypertensive and lipid-lowering therapy. The drug is indicated for adult patients with both hypertension and dyslipidemia, offering an effective option for those needing control of both blood pressure and LDL cholesterol[1][3][5]. Clinical studies have demonstrated its efficacy in reducing blood pressure as well as low-density lipoprotein cholesterol levels[3][5].
- Brand names
- Amosartan QTristanium
- Other names
- amlodipine + losartan + rosuvastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on Amosartan Q.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amosartan Q.